Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Harvest Lane Asset Management. This analysis is provided for institutional research purposes only and is not investment advice.
"The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the fund proactively trimmed its position to limit drawdown damage."
Harvest Lane Absolute Return Fund rebounded in June 2025 with a 3.40% return, bringing FY25 YTD returns to 9.21%. The primary focus of the commentary is May 2025's drawdown (-2.55%), which was 80% driven by a position in Mayne Pharma Group (MYX.ASX). US private equity-backed Cosette Pharmaceuticals issued a Material Adverse Change (MAC) notice to walk away from its agreed acquisition of Mayne Pharma at $7.40/share. While Harvest Lane strongly believes Cosette has no legal grounds to walk away and that Mayne Pharma should enforce the contract in court, the manager proactively cut a significant portion of its position to manage downside risk, citing the 'Law of Large Losses' (where a -50% loss requires a +100% gain to break even).
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Growth Outlook
Market outlook remains above average conviction: The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Risk Appetite
Risk appetite posture is moderate conviction: The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Forward Guidance
Forward guidance signal: The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Language Signal
Tone analysis indicates above average conviction language: The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
Time Horizon
Investment time horizon reflects a above average conviction orientation. The fund returned 3.40% in June 2025 after managing a major M&A deal dispute between Mayne Pharma and Cosette. While confident that the buyer has no legal grounds to walk away, the...
